|Home | About | Journals | Submit | Contact Us | Français|
Systemic modulation of Group I and II metabotropic glutamate receptors (mGluRs) regulate ethanol self-administration in a variety of animal models. Although these receptors are expressed in reward-related brain regions, the anatomical specificity of their functional involvement in ethanol self-administration remains to be characterized. This study sought to evaluate the functional role of Group I (mGluR5) and Group II (mGluR2/3) in mesocorticolimbic brain regions in ethanol self-administration.
Alcohol-preferring (P) rats, a genetic model of high alcohol drinking, were trained to self-administer ethanol (15% v/v) versus water in operant conditioning chambers. Effects of brain site-specific infusion of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP) and the mGluR2/3 agonist were then assessed on the maintenance of self-administration.
Microinjection of the mGluR5 antagonist MPEP in the nucleus accumbens reduced ethanol self-administration at a dose that did not alter locomotor activity. By contrast, infusion of the mGluR2/3 agonist LY379268 in the nucleus accumbens reduced self-administration and produced nonspecific reductions in locomotor activity. The mGluR5 involvement showed anatomical specificity as evidenced by lack of effect of MPEP infusion in the dorsomedial caudate or medial prefrontal cortex on ethanol self-administration. To determine reinforcer specificity, P-rats were trained to self-administer sucrose (.4% w/v) versus water, and effects of intra-accumbens MPEP were tested. The MPEP did not alter sucrose self-administration or motor behavior.
These results suggest that mGluR5 activity specifically in the nucleus accumbens is required for the maintenance of ethanol self-administration in individuals with genetic risk for high alcohol consumption.
The amino acid glutamate is the primary excitatory transmitter in the mammalian brain. Fast excitatory actions of glutamate are mediated by ionotropic N-methyl-D-aspartate (NMDA), α-amino-3-hydroxi-5-methyl-ioxyzole-4-propionic acid (AMPA), and kainite (KA) receptors. Metabotropic glutamate receptors (mGluRs) mediate slower glutamate responses through G-protein coupling to various intracellular signaling cascades that can modulate ionotropic receptor function (1). In addition to its well-known effects on ionotropic glutamate receptor function (2–9), ethanol modulates general metabotropic receptor activity as evidenced by reduced basal and stimulated phosphoinositide hydrolysis (10).
The mGluRs comprise eight subtypes categorized into three groups according to similar properties, such as sequence homology, molecular structure, selective pathways of signal transduction, and pharmacological profiles (11–13). Group I receptors (mGluR1 and mGluR5) are coupled to Gq, stimulate phospholipase C and phosphoinositide hydrolysis (14,15), are predominantly located postsynaptically, and modulate neuronal signaling and cellular excitability (16). The Group II (mGluR2 and 3) and Group III (mGluR4, 6, 7, and 8) family of receptors couple to Gi, a pathway that inhibits cyclic adenosine monophosphate formation upon activation (16,17), and are predominantly located presynaptically but have also been localized postsynaptically (18) and function to regulate glutamate release to appropriate physiological levels (17). The mGluRs regulate a variety of neurobiological processes, such as learning and memory, synaptic plasticity, and modulation of ionotropic glutamate and γ-aminobutyric acid (GABA) receptor activity, as well as facilitating glutamate release (16,19–22). Low concentrations of ethanol selectively alter neuronal firing rates (23) and Ca2+ levels (24) mediated by mGluRs in vitro, which suggests that ethanol has direct actions on mGluR activity.
Although the neurobiological substrates that regulate the positive reinforcing effects of ethanol remain to be fully characterized, the mesolimbic system has received considerable attention because of its general involvement in reinforcement (25–28) and drug self-administration (29–32). Early studies focused on dopamine neurotransmission within this system, because acute injection of ethanol was found to increase extracellular dopamine levels in the nucleus accumbens (33). Infusion of dopamine agonists in the nucleus accumbens increases ethanol-reinforced responding, whereas D1 and D2 receptor antagonists produce decreases (29,34,35). Similarly, microinjection studies have shown that intra-accumbens systems that interact with dopamine—including GABA-A (36,37), opiate (38,39), and endocannabinoid CB1 (40) receptors—regulate ethanol reinforcement. Evidence also shows that ethanol injection increases glutamate levels in the nucleus accumbens (41) and NMDA receptor antagonist infusion in the nucleus accumbens decreases ethanol-reinforced responding (42,43), which underscores the potential importance of mesolimbic glutamate in this process.
Group I and II mGluRs are highly expressed in the mesocorticolimbic system. mGluR5s and mGluR2/3s are abundant in regions such as the nucleus accumbens, lateral septum, striatum, amygdala, and hippocampus (15,44–46). Alternatively, mGluR1s show low expression in most limbic brain regions but are highly expressed in the cerebellum where they regulate motor coordination (47). This differential mesocorticolimbic distribution pattern of mGluR subtypes suggests that mGluR5 and mGluR2/3 might regulate ethanol reinforcement, but mGluR1 might not. Indeed, systemically administered mGluR5 antagonists and mGluR2/3 agonists have been shown to modulate cocaine, nicotine, and ethanol reinforcement and drug-seeking behavior in reinstatement models (48–55). By contrast, mGluR1 receptor modulation of ethanol self-administration is attributable to nonspecific motor impairment (56,57). Furthermore, evidence from site-specific infusion studies shows that ethanol self-administration is modulated by activity of specific brain regions, including the nucleus accumbens and frontal cortex (29,35,36,42,58), that express high levels of mGluR5 and mGluR2/3. Accordingly, the present study was designed to examine the direct functional involvement of mGluR5 or mGluR2/3 expressed in mesocorticolimbic brain regions in ethanol reinforcement.
Because individuals with variation in the mGluR5 gene (GRM5) show significant risk for developing alcohol dependence (59), we sought to examine the functional involvement of mesocorticolimbic mGluR5 and mGluR2/3 in ethanol reinforcement in alcohol-preferring (P) rats, a prominent genetic model of high alcohol intake (60). The P-rat line has been found to fulfill the requirements of an animal model of alcoholism (61), because these rats voluntarily consume alcohol in quantities that produce significant blood alcohol concentrations, develop tolerance and dependence through voluntary drinking (62–64), and maintain preference for ethanol when palatable solutions are presented as an alternative (65). Briefly, P-rats were trained to self-administer ethanol (15% v/v) and then received surgical implantation of bilateral injector cannulae aimed at the nucleus accumbens core; however, no attempt was made to differentiate between subnuclei of the accumbens (e.g., core vs. shell), because the extent of drug diffusion is greater than the anatomical distance between these structures (66). After surgery, effects of intra-accumbens infusion of the mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP) and the mGluR2/3 agonist (1R,4R,5S,6R)-4-amino-2-oxabicyclo(3.1.0)hexane-4,6-dicarboxylic acid (LY379268) on the maintenance of ethanol self-administration were determined. The mGluR5 antagonist was also tested in the dorsomedial striatum and medial prefrontal cortex (mPFC) to further examine anatomical specificity of mGluR5 involvement in ethanol-reinforced responding. To assess reinforcer specificity, the mGluR5 antagonist was administered in the nucleus accumbens of P-rats trained to self-administer sucrose (.4% w/v) versus water. Finally, locomotor assessments were conducted after site-specific infusion of mGluR5 or mGluR2/3 compounds to determine whether reductions in self-administration were associated with nonspecific motor impairments.
See Supplement 1 for detailed methods.
Male ethanol-preferring rats were trained to self-administer ethanol (15% v/v) versus water during daily (Monday–Friday) 30-min sessions in operant conditioning chambers with a sucrose-fading procedure (67) as previously described (36,50,57,68). After sucrose fading, self-administration sessions with ethanol (15% v/v) and water as the reinforcers continued for the remainder of the study. After completion of 28 baseline self-administration sessions with 15% ethanol, rats underwent surgery for cannulae implantation
Rats were habituated to the microinjection procedure by receiving a sham infusion as the initial test. For testing of the mGlu receptor compounds, rats received a bilateral microinjection of a single MPEP (0 μg, 1 μg, 3 μg, 10 μg; n = 6) or LY379268 (0 μg, .03 μg, .1 μg, .17 μg; n = 9) dose in randomized order. After injectors were removed, rats were placed in the chambers for a self-administration session (30 min). Test sessions were interspersed with training sessions with at least two self-administration sessions between tests. The MPEP and LY379268 dose order was randomized.
After the mGlu receptor compound evaluation on ethanol self-administration, the lowest effective dose of MPEP and LY379268 that reduced ethanol self-administration was evaluated to determine whether the reductions in ethanol self-administration were accompanied by motor impairments. Rats were administered the same mGluR compound tested in self-administration, either MPEP (0 μg, 10 μg) or LY379268 (0 μg, .17 μg), and immediately placed in the activity chambers for 30-min sessions. Dose order was randomly assigned, and each rat experienced two locomotor sessions. Locomotor sessions were interspersed with self-administration sessions with at least 3 days between tests. Self-administration sessions were withheld on the days of the locomotor assessments.
Rats received implantation of bilateral cannulae aimed at the dorsomedial caudate putamen (n = 9) or the mPFC (n = 7). Rats were habituated to the microinjection procedure and then administered MPEP (0 μg, 1 μg, 3 μg, 10 μg; dorsomedial caudate) or MPEP (0 μg, 1 μg, 3 μg, 10 μg, 30 μg; mPFC) in random dose order with at least two baseline sessions between tests. After the self-administration assessment, effects of MPEP (dorsomedial caudate: 0 μg, 10 μg; mPFC: 0 μg, 30 μg) were tested on motor activity with the same procedure as previously described.
Rats were trained to self-administer sucrose (.4% w/v) versus water with procedures as described for ethanol self-administration with the exception that ethanol was never present in the solution. This concentration of sucrose was chosen because we have previously shown that this dose results in similar baseline responding as 15% v/v ethanol (56,57). After 22 baseline sessions, rats received implantation of bilateral cannulae aimed at the nucleus accumbens. Effects of presession administration of MPEP (0 μg, 1 μg, 3 μg, 10 μg, 30 μg; n = 8) in nucleus accumbens was then evaluated on sucrose self-administration as described for ethanol. After the self-administration assessment, effects of MPEP (0 μg, 30 μg) were tested on motor activity with the same procedure as previously described.
Ethanol (95%) was diluted in distilled water. The MPEP (Sigma Aldrich, St. Louis, Missouri), a selective antagonist of mGluR5 (69), and LY379268 (Tocris, Ellisville, Missouri), a selective Group II (mGluR2/3) agonist (70), were dissolved in artificial cerebrospinal fluid (aCSF).
Total responses on the ethanol (or sucrose) and water levers and ethanol intake (g/kg) were analyzed by a one-way repeated measures analysis of variance (RM ANOVA) with Dunnett post hoc analyses. Cumulative ethanol responses and locomotor activity during the 30-min sessions were analyzed with a two-way RM ANOVA with Tukey post hoc comparisons to extract significant main effects and interactions. Statistical significance was declared at p ≤ .05.
Average baseline data (mean ± SEM) for the 2 days preceding the sham test of MPEP and LY379268 on ethanol self-administration are shown in Table 1. Histological verification showed that injection sites were in the nucleus accumbens core (Figures 1A and 1B). Intra-accumbens infusion of the mGluR5 antagonist MPEP significantly reduced total session ethanol (15% v/v) responding [F(3,15) = 4.65, p < .02] (Figure 2A). No MPEP-induced changes in water responses were evident. Ethanol intake (g/kg) was also significantly reduced by MPEP [F(3,15) = 4.65, p = .02], with significantly reduced ethanol intake at the highest MPEP dose (10 μg; Table 2). Cumulative ethanol responses were examined to determine the pattern of ethanol responding across the 30-min session (Figure 2B). The two-way RM ANOVA showed a significant main effect of time [F(5,25) = 45.25, p < .001], a significant main effect of MPEP dose [F(3,15) = 4.97, p < .01], and a significant interaction [F(15,75) = 1.88, p < .04], with a significant MPEP (10 μg)-induced reduction in ethanol-reinforced responding during the last half of the session (p values < .03). In the locomotor assessment, the dose of MPEP (10 μg) that reduced ethanol-reinforced responding did not alter activity across the 30-min session (Figure 2C). The two-way RM ANOVA showed a significant increase in activity over time [F(14,56) = 28.81, p < .001], with no significant main effect of MPEP dose or dose × time interaction.
Intra-accumbens administration of the mGluR2/3 agonist LY379268 also significantly reduced total session ethanol responses [F(3,17) = 3.76, p = .03] (Figure 2D) and ethanol intake [F(3,17) = 4.19, p = .02] (Table 2). Water responses were unchanged by LY379268 pretreatment. As shown in Figure 2E, analysis of the cumulative ethanol responses showed a significant main effect of time [F(5,25) = 12.90, p < .001] and a significant interaction [F(15,75) = 2.99, p < .001], with reduced ethanol responding relative to vehicle during the last half of the session (p values ≤ .02) after treatment with the highest LY379268 dose (.17 μg). The dose of LY379268 (.17 μg) that decreased ethanol-reinforced responding produced a significant reduction in locomotor activity, because examination of the cumulative distance traveled across the 30-min session showed a significant main effect of LY379268 dose [F(1,5) = 8.42, p = .03], a significant main effect of time [F(14,70) = 46.10, p < .001], and a significant LY379268 dose × time interaction [F(14,70) = 5.21, p < .001] (Figure 2F). The LY379268-induced reduction in cumulative distance emerged at min 12 and continued throughout the session (p values ≤ .04).
Average baseline data (mean ± SEM) for both the dorsomedial caudate and mPFC group for the 2 days preceding the sham infusion are shown in Table 1. Dorsomedial caudate administration (Figures 1C and 1D) of MPEP did not alter ethanol (15% v/v) self-administration (Figure 3A) or ethanol intake (g/kg; Table 2). Analysis of cumulative ethanol responses across the 30-min session indicated a significant main effect of time [F(5,25) = 29.27, p < .001] but no main effect of MPEP dose or interaction (Figure 3B). Interestingly, intracaudate MPEP induced a significant increase in total session water responding (Table 3) at the highest MPEP dose [10 μg; F(3,17) = 3.28, p = .046]. Intracaudate administration of the highest dose of MPEP (10 μg/μL) did not alter cumulative locomotor activity (Figure 3C). An ANOVA showed a significant effect of time only [F(14,84) = 57.50, p < .001], with no effect of MPEP and no MPEP × time interaction.
Intra-mPFC administration of MPEP in the mPFC (Figures 1E and 1F) did not significantly alter total ethanol (Figure 3D) or water responses (Table 3). Analysis of the pattern of response across time showed a significant main effect of time [F(5,20) = 17.85, p < .001]. The main effect of intra-mPFC MPEP dose and the interaction were not significant (Figure 3E). The highest dose of MPEP (30 μg/μL) tested in the mPFC produced no effect on cumulative locomotor activity (Figure 3F), with ANOVA confirming only a significant effect of time [F(14,56) = 59.57, p < .001]. No significant main effect of MPEP dose or interaction was observed on locomotor activity.
Average baseline data (mean ± SEM) for the 2 days preceding the sham test of MPEP on sucrose self-administration are shown in Table 1. Nucleus accumbens administration (Figures 1A and 1D) of MPEP did not alter sucrose self-administration (.4% w/v; Figure 4A). Water-responding was also not altered by MPEP pretreatment (Table 3). Analysis of cumulative sucrose responses across the 30-min session indicated a significant main effect of time [F(5,25) = 31.94, p < .001] but no main effect of MPEP dose (Figure 4B). A significant interaction was found [F(20,100) = 1.98, p = .01]; however, sucrose-reinforced responding after intra-accumbens MPEP administration did not significantly differ from aCSF at any time point throughout the session.
Intra-accumbens administration of the highest MPEP dose tested (30 μg) did not alter spontaneous motor activity in sucrose-exposed rats (Figure 4C). Analysis of the cumulative distance traveled across the 30-min session showed a significant main effect of time [F(14,84) = 44.18, p < .001] but no main effect of MPEP dose or interaction.
This study was designed to investigate functional involvement of nucleus accumbens mGluR5 and mGluR2/3 in ethanol reinforcement in the alcohol-preferring P-rat line, which is a prominent genetic model of excessive alcohol-drinking (64). Accordingly, P-rats self-administered relatively high levels of ethanol (range .74 g/kg–1.32 g/kg) during 30-min operant sessions, for which we have shown results in blood ethanol levels of approximately 80 mg/dL (57). Results showed that pharmacological inhibition of mGluR5 in the nucleus accumbens produced a 70% reduction in ethanol self-administration in the absence of nonspecific effects on motor activity. Functional specificity of mGluR5 was confirmed, because activation of mGluR2/3 in the nucleus accumbens did not selectively alter ethanol self-administration. Blockade of mGluR5 in two other brain regions (mPFC and dorsomedial caudate) produced no effect on ethanol self-administration, indicating anatomical specificity of mGluR5 function in this behavior. Furthermore, ethanol specificity was confirmed, because intra-accumbens mGluR5 antagonism did not alter self-administration of another reinforcing solution (i.e., sucrose). These results indicate mGluR5 activity in the nucleus accumbens is required for the full expression of ethanol's reinforcing effects in individuals with a genetic predisposition for heavy alcohol-drinking.
Previous work has determined a role for mGluR5 in ethanol reinforcement as evidenced by reductions in ethanol self-administration after systemic administration of mGluR5 antagonists (48–51,56,71). This study shows that infusion of the mGluR5 antagonist MPEP (0 μg–10 μg) in the nucleus accumbens reduces ethanol-reinforced responding. The mGluR5 antagonism, or gene knockout, has been shown to potentiate ethanol's acute sedative-hypnotic effects and produce motor impairments after moderate alcohol doses (72–74); thus, examination of the temporal pattern of responding was critical for the interpretation of the total session reductions in ethanol self-administration. Intra-accumbens mGluR5 antagonism produced a general suppression of ethanol-reinforced responding throughout the 30-min self-administration session, indicating that MPEP effects were independent of consumed ethanol. Furthermore, the prolonged suppression of ethanol-reinforced responding across the 30-min session is consistent with the time course of mGluR5 occupancy after systemic MPEP injection (i.e., full receptor occupancy sustained for at least 1 hour (75). Finally, the reduction in ethanol self-administration is likely not related to drug substitution, because mGluR5 antagonism itself does not produce ethanol-like properties and does not alter the subjective properties of low ethanol dose (76–78).
The results of this study complement other evidence showing that glutamate transmission in the nucleus accumbens regulates ethanol reinforcement. Microinjection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of Wistar rats reduced ethanol-reinforced responding (42). The present study extends this work by showing that inhibition of mGluR5 but not mGluR2/3 activity specifically in the nucleus accumbens reduces the maintenance of ethanol-reinforced responding in P-rats that were self-administering relatively high doses of ethanol under control conditions (mean 1.04 g/kg/30-min session). Thus, it seems that disrupting glutamate neurotransmission either through blockade of postsynaptic ionotropic NMDA or metabotropic mGluR5 in the nucleus accumbens is sufficient to prevent the full expression of ethanol's reinforcing properties.
mGluR5s are widely expressed throughout the striatum (44), with similar expression in the nucleus accumbens and caudate putamen (76,79,80). However, infusion of MPEP in the dorsomedial caudate, contrary to the nucleus accumbens infusion, had no effect on ethanol self-administration. The dorsal striatum has been shown to regulate cocaine self-administration by dopamine and AMPA/kainate receptors (81) and ethanol self-administration by NMDA (NR2B) receptors (82). Furthermore, the dorsal striatum has been implicated in learning stimulus-response relations associated with habit formation (83). Given that compulsive/habitual drug use—a hallmark of drug addiction—can be regarded as maladaptive stimulus-response relations, the dorsal striatum has become a region of significant interest in the drug abuse field (84). Although the present findings suggest that mGluR5 within this region do not modulate the maintenance of ethanol-reinforced responding, a partial trend was observed at the highest dose of MPEP tested, suggesting that an extended dose range of MPEP or another mGluR5 antagonist such as 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine might show efficacy. It will also be both interesting and important for future work to determine whether mGluR5 in the dorsal striatum regulate other aspects of ethanol-seeking behavior that rely on conditioned reinforcement, such as cue-induced reinstatement.
Functional specificity of nucleus accumbens mGluR5 was further evaluated by examining the effects of MPEP infusion in the mPFC on the maintenance of ethanol self-administration. The mPFC was tested for several reasons. First, this brain region has been shown to modulate ethanol self-administration (58,85,86), and low doses of ethanol increase extracellular glutamate levels in the mPFC of alcohol-preferring Lewis rats (87). Second, mGluR5 regulate firing rate of mPFC neurons (88), which is a neural correlate of reward prediction (89). Third, the mPFC sends glutamatergic projections to the nucleus accumbens, and inactivation of the mPFC reduces the firing rate of nucleus accumbens neurons in response to reward-predictive cues (90). Thus, inhibition of postsynaptic mGluR5 in the mPFC might alter ethanol self-administration via local mechanisms or by dampening mPFC glutamatergic inputs to the nucleus accumbens. Results showed, however, that infusion of the mGluR5 antagonist MPEP in the mPFC had no effect on ethanol self-administration. This was evident even though a higher MPEP dose range was tested in the mPFC compared with the nucleus accumbens. These findings suggest that mGluR5 in the mPFC are not involved in the regulation of the maintenance of ethanol self-administration. However, because the mPFC regulates response to predictive cues, mGluR5 in this brain region might influence behaviors that are regulated by associative learning, such as cue-induced reinstatement of ethanol seeking.
Specificity of nucleus accumbens mGluR5 was further confirmed by testing the role of mGluR2/3 in ethanol self-administration. Intra-accumbens mGluR2/3 activation reduced ethanol self-administration. This was evident by a reduction in total session ethanol-reinforced responding and a pattern of suppression similar to that observed after mGluR5 antagonism (i.e., general suppression of responding throughout the session). These results are consistent with evidence showing that intra-accumbens infusion of the mGlu2/3 agonist APDC reduced ethanol-drinking in a 4-bottle home-cage procedure by C57Bl/6 J and DBA2/J mice (91). However, results from the present study showed that LY379268 also reduced spontaneous motor activity, suggesting that reductions in ethanol-reinforced responding were likely due to a motor impairment. This finding is consistent with the findings of a study by Backstrom and Hyytia (92) in which a systemically administered mGluR2/3 agonist produced a significant reduction in ethanol self-administration at a dose that was accompanied by a motor impairment (but see ). Given that LY379268 decreased ethanol self-administration only at a dose that produced nonspecific reductions in locomotor activity, these findings indicate that mGluR2/3 activation in the nucleus accumbens does not selectively modulate the maintenance of ethanol self-administration. However, because systemically administered mGluR2/3 agonists exhibit efficacy in other behavioral procedures, such as models of relapse, anxiety, and stress reactivity during abstinence (93–95), future work might determine a more selective role of intra-accumbens mGluR2/3 in these pathological behaviors.
To determine whether mGluR5 in the nucleus accumbens produces a reduction in the maintenance of self-administration of a rewarding substance in general, intra-accumbens mGluR5 antagonism was assessed in rats trained to self-administer sucrose versus water. Baseline level of sucrose (.4% w/v) self-administration was similar to the baseline ethanol self-administration, consistent with our previous findings (56,57). Accordingly, differences in self-administration behavior between the sucrose and ethanol group cannot be attributed to differential effects of the mGluR5 antagonist on response rate. Intra-accumbens antagonism was without effect on sucrose self-administration, even as an mGluR5 antagonist dose range higher than for ethanol self-administration was tested. This finding suggests specificity of the effects of mGluR5 antagonism to ethanol reinforcement and also confirms the lack of antagonist-induced nonspecific motor effects. Furthermore, the dissociation of mGluR5 involvement in ethanol versus sucrose reinforcement is similar to the findings of another study in which motivation to self-administer ethanol but not sucrose was reduced after systemic mGluR5 antagonism (57). Overall, some studies have shown reductions in food-reinforced behavior after mGluR5 antagonism (96,97), whereas other studies have not (53,98,99). However, the present results are consistent with another study that showed no change in sucrose self-administration after intra-accumbens mGluR5 antagonism (100). Together, this data pattern supports a role for intra-accumbens mGluR5 in the selective modulation of ethanol self-administration.
One issue that should be discussed when considering mGlu receptor subtype specificity relates to the selectivity of mGlu receptor compounds tested. Studies have emerged showing that the mGluR5 antagonist MPEP modulates the activity of other receptor systems. For instance, MPEP has been shown to blunt NMDA-evoked currents (101), inhibit the norepinephrine transporter (102), and act as a positive allosteric modulator of mGlu4 receptors (103). The mGluR2/3 agonist LY379268 has recently been shown to stimulate dopamine D2 receptors (104). Moreover, MPEP infused in the nucleus accumbens inhibits intra-accumbens mGluR5 agonist-induced GABA release in the ventral pallidum (105). Because these receptor systems have been shown to modulate ethanol self-administration or voluntary ethanol-drinking (29,82,106–108), it is possible that mGluR5 inhibition in the nucleus accumbens reduced ethanol self-administration via nonspecific pharmacological effects or regulation of associated neural circuit(s).
In conclusion, there is growing interest in developing mGlu receptor compounds as therapeutics for drug and alcohol use disorders (109), because these compounds have been shown to reduce self-administration and relapse to drug-taking of several drugs of abuse (54,110–112), including alcohol (48–51,56,57,71,91–93,113). The results of this study extend the previous literature to show that inhibition of mGluR5 activity in the nucleus accumbens, a key component of the brain's reward pathway, specifically reduces operant ethanol self-administration. These data confirm the importance of mGluR5 activity in the nucleus accumbens in regulating drug reinforcement and emphasize the potential therapeutic utility of targeting this receptor system in individuals with genetic risk for excessive drinking.
This work was supported by grants from the National Institute on Alcohol Abuse and Alcoholism to JB (AA016009) and CWH (AA014983 and AA011605).
The authors report no biomedical financial interests or potential conflicts of interest.
Supplementary material cited in this article is available online.